SUPN Supernus Pharmaceuticals, Inc.
Distress ·
Supernus ended its UBS credit line on October 20, 2026, with nothing drawn and no penalty. The filing says the combined company is to enter a new senior secured facility at closing, but it gives no closing date and no terms.
Supernus (Nasdaq: SUPN) took on Sage's New York class action naming Barry Greene and Kimi Iguchi, three derivative suits against sixteen unnamed insiders, and an SEC subpoena. Supernus faces two merger suits of its own.
Supernus and Indivior agreed to an all-stock merger that includes a $1.0 billion cash dividend to Indivior stockholders. The companies say a $650 million Citibank term loan commitment will help fund it, and they expect the deal to close in the fourth quarter of 2026.
Sage Chemical and TruPharma sued Supernus, Britannia, US WorldMeds and others in Delaware. Four individuals were dismissed in 2024. Insurance coverage suits tied to an unnamed Delaware action are open.
Supernus agreed on April 1, 2026 to buy the NV-5138 assets from Navitor. The price is an obligation to complete one Phase 2b study plus milestone payments of up to $350 million, and Supernus may stop pursuing the milestones if it judges the study unsuccessful.
Supernus completed its acquisition of Sage Therapeutics on July 31, 2025 after a tender offer, paying $8.50 in cash per share plus a contingent value right worth up to $3.50. The filing puts the cash consideration at about $561 million, and says no CVR payment is assured.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for central nervous system diseases. Its approved treatments address attention-deficit hyperactivity disorder, dyskinesia and OFF episodes in Parkinson's disease, postpartum depression, epilepsy, migraine, cervical dystonia and chronic sialorrhea. Qelbree is a non-stimulant treatment for ADHD in adults and pediatric patients. GOCOVRI is indicated for dyskinesia in Parkinson's patients receiving levodopa-based therapy. ZURZUVAE is the first and only FDA approved oral medicine indicated for postpartum depression in adults and became commercially available in the U.S. in December 2023. Biogen is the collaboration partner jointly commercializing ZURZUVAE. The company completed its acquisition of Sage Therapeutics, Inc. on July 31, 2025, at $8.50 per share in cash plus one contingent value right per share, worth up to $3.50 per share. The company also markets Trokendi XR, Oxtellar XR and APOKYN and has several product candidates in development.
| Product or program | What it is | Stage |
|---|---|---|
| Qelbree | Viloxazine extended-release non-stimulant for ADHD | approved |
| GOCOVRI | Amantadine extended-release capsules for dyskinesia in Parkinson's disease | approved |
| APOKYN | Apomorphine injection for OFF episodes in advanced Parkinson's disease | approved |
| Trokendi XR | Once-daily extended-release topiramate for epilepsy and migraine prevention | approved |
| Oxtellar XR | Once-daily extended-release oxcarbazepine for partial-onset seizures | approved |
| ZURZUVAE | Oral neuroactive steroid for postpartum depression in adults | approved; commercially available in the U.S. |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $106.2 million | $108.8 million |
| Net income (loss) | -$38.5 million | $73.9 million |
| Cash from operations | $47.3 million | $172.0 million |
| Cash and equivalents | $128.4 million | $69.3 million |
Our latest story on this, dated Oct 15, 2026: "Supernus inherits Sage securities class action, derivative suits and SEC subpoena". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 26, 2026: "Supernus ends its UBS credit line ahead of the Indivior merger". The story links the filing or release it is based on. Read the story.
Supernus Pharmaceuticals, Inc. trades under the ticker SUPN on NASDAQ.
Supernus Pharmaceuticals, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:S49; LSE:0LB2; LSX:A1JX3U.
The SEC Central Index Key (CIK) for Supernus Pharmaceuticals, Inc. is 1356576. Its filings are on SEC EDGAR.
58,127,013 shares as of 2026-07-28, per the cover page of its 10-Q filed 2026-08-03.
Our directory records Supernus Pharmaceuticals, Inc. under United States.
Our directory classifies Supernus Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Supernus Pharmaceuticals, Inc. is US8684591089.
aibio.space lists Supernus Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for central nervous system diseases. Its approved treatments address attention-deficit hyperactivity disorder, dyskinesia and OFF episodes in Parkinson's disease, postpartum depression, epilepsy, migraine, cervical dystonia and chronic sialorrhea.
Qelbree: Viloxazine extended-release non-stimulant for ADHD Stage: approved.
GOCOVRI: Amantadine extended-release capsules for dyskinesia in Parkinson's disease Stage: approved.
Supernus Pharmaceuticals, Inc. reported a net loss of $38.5 million for the fiscal year ended Dec 31, 2025, and generated $47.3 million of cash from operations, per its annual report to the SEC.
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). Source
Filed documents for a merger or acquisition. SEC Form 425. Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,5.02,8.01,9.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,8.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio